Erythropoietin gene therapy - ValentisAlternative Names: EPO/Switch; EpoSwitch; EpoSwitch GeneMedicine
Latest Information Update: 19 Sep 2008
At a glance
- Originator Valentis
- Class Antianaemics; Gene therapies; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 19 Sep 2008 Updated MoA
- 24 May 2001 Erythropoietin gene therapy in combination with EPOSwitchTM is available for licensing (http://www.valentis.com/)
- 06 Jun 2000 Preclinical development for Anaemia in USA (IM)